

Working Group Health Economics (2020-2021)

- Board selected
 - Lionel Perrier (Fr)
 - Davide Galegati (It)
 - Edit Porcnechy (Hu)
 - Michael Schlander (Ge) replaced Raul Kiivet (Est)
 - Marien van der Meer (NL) board representative
 - Valesca Retel (NL) Coordinator
 - WvH (NL) Chair.
- 3 Board meetings,
- 2 Working group meetings with ± 30 participants.
- Scientific session in Annual Scientific Meeting 16/6 and
- 3rd Working Group meeting 17/6 planned.

Working Group Health Economics


- Support and Liaison with European Fair Pricing Network (EFPN) (exposure in Eu press, Eu parliament and with Commissioners).
- Participation of Chair in EACS working group on Health Economics (paper in preparation)
- (SUB)Task Force on Methods in Assessing Socio Economic Consequences of Cancer, initiated and chaired by Michael Schlander
- Bottom up project on dual/combined treatments
- Granted: "One-shot project":
 - Trial on socio-economic consequences for cancer patients



Working Group Health Economics

- Knowledge and project exchange
- Execution network of Health Economics projects
- Positioning OECI in this field
- 3 WG meetings 2021-2022
- Inviting new project proposals.





3 Projects with OEI - EFPPN

1. Interviews with hospital pharmacists


- Patient access to cancer medicine and availability of drugs

2. OEI survey for oncologists

- Use of Targeted Combination Therapy

3. One Shot Patient-trial: for hospitals and patient organizations

- Socio-economic consequences trial for cancer patients
- "One-shot grant OEI"



Project 1.

Patient access to cancer medicine and availability of drugs

- EFPN initiated project
- Interviews and surveys with hospital pharmacists
 - Currently ongoing
- Focus on direct patient access to innovative cancers medicines
- Represent your country? Contact j.vancoppenolle@nki.nl




REIMBURSEMENT STATUS (NOV-DEC 2020)



Countries/Medicines	Pembrolizumab	Nivolumab	Olaparib	Niraparib	Durvalumab	Ipilimumab	Pertuzumab	Trastuzumab emtansine	Palbociclib	Osimertinib	Tisagenlecleucel	Larotrectinib
Austria	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	X	✓
Belgium	✓	✓	✓	X	✓	✓	✓	✓	✓	✓	✓	X
Bulgaria	✓	✓	✓	X	✓	✓	✓	✓	✓	✓	✓	X
Czechia	✓	✓	✓	✓	X	✓	✓	✓	X	✓	X	X
Estonia	✓	X	✓	X	X	X	X	X	✓	✓	X	X
France	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓	✓
Latvia	✓	X	✓	X	✓	✓	✓	✓	✓	✓	X	X
Lithuania	✓	✓	✓	X	✓	X	X	X	X	X	X	X
The Netherlands	✓	✓	✓	✓	✓	✓	✓	X	✓	✓	✓	X
Poland	✓	✓	✓	X	X	✓	✓	✓	✓	✓	X	X
Slovenia	✓	✓	✓	X	✓	✓	✓	✓	✓	✓	✓	X

X Not reimbursed/ not found on the list of reimbursed medicines
✓ Reimbursed but not all formula's
✓ All formula's reimbursed

AU: <https://www.sozialversicherung.at/oeko/views/index.xhtml>
 BE: www.inami.fgov.be
 NL: <https://www.horizonscangeneesmiddelen.nl>
 CZ: <http://www.sukl.eu>
 LV: <https://www.zva.gov.lv>
 EST: <https://www.ravimiregister.ee>
 PL: <https://www.dlaprzejrzystosci.pl>



Time from EMA approval to patient access in three different hospitals



Categorization

Facilitators & Barriers

Supply side

Demand side

Reimbursement criteria

Special policies for expensive medicines

Early access schemes

Hospital

Physician

Patient

Market access agreements (uncertainty)

Quicker reimbursement & pricing procedure

Nationally implemented

Separate budget for patients in need

High frequency of clinical guideline updates

Cap on out-of-pocket expenditures

Lack of clarity of national requirements

Lack of adherence to maximum timelines

Decentralized procedure


Multiple layers of decision-making

Insufficient budget to implement decisions

High co-payments & healthcare costs


Project 2.

Use of targeted combination therapy



- OEI initiative, working-group health economics
- Survey for lung cancer specialists
 - Focus on: use of expensive drug combinations
 - Targeted therapy, immunotherapy, tyrosine kinase inhibitors
- Survey will be send out to OEI in June 2021
 - Make sure to forward to clinicians (lung cancer specialists)
 - More info: s.koole@nki.nl

Project in collaboration with:
Dr L. Perrier, Lyon, France
Dr J. O'Mahony, Dublin, Ireland



Project proposal

- Part 1: Conduct a survey among **clinicians** in OEI centers
 - Focus on melanoma, colorectal, lung
 - Availability
 - Overview of TCT use in European member states
 - Use of TCTs in OEI centers: is it homogenous?
 - National and regional policies & decision making around TCTs
 - Implementation issues & compliance:
 - Are combinations used with national “permission”?



Combinations included in survey: Melanoma, lung, colorectal

- nivolumab + ipilimumab
- pembrolizumab + axitinib
- Encorafenib + cetuximab
- Encorafenib + binimetinib + cetuximab
- Encorafenib + binimetinib
- Dabrafenib + trametinib
- Dabrafenib + trametinib + pembrolizumab
- Vemurafenib + cobimetinib
- Ramucirumab + erlotinib
- Erlotinib + bevacizumab
- Atezolizumab + bevacizumab

BRAF-I

MEK-I

EGFR-I

immunotherapy



Aims of the interview

Part 2

Aim: to explore and compare the National initiatives on TCT in terms of policy and decision making across European countries

- Identify the stakeholders involved in TCT prescriptions/authorizations
 - government agencies, research institutions, health care professionals, manufacturers, etc.
- Conduct a qualitative study based on semi-structured interviews
- Focus on policies & pricing, HTA

Call for: national experts, policy makers, HTA experts, decision makers on drug approval




Project 3.

One Shot OEI project: Socio-economic consequences for cancer patients

Project in collaboration with:
Prof. M. Schlander, Heidelberg,
Germany

- OEI initiative, working-group health economics
- Granted by OEI: “One shot project”
- Assess the socio-economic distress after cancer diagnosis
 - patient perspective
 - multi-country / European framework
- Distribution of a survey among patients through hospitals and patient organizations
 - **Aim: 200 patient participants per country**
- Represent your country? Contact sectrial@nki.nl





Project 3. Socio-economic consequences for cancer patients



Protocol,
Informed consent
& questionnaire
design

dkfz.

NKI IRB
approval

Launch
prep

Questionnaire
distribution

Patient organisations

Hospitals


**Any
institution/organization
is welcome to
participate!**

Collaboration confirmed with:

- European Cancer Patient Coalition (EU)
- Asociación Española Contra el Cáncer (ES)
- Vivre Sans Thyroïde (FR)
- Cancer Support France (FR)
- PASYKAF (CY)
- Danish Cancer Society (DK)
- Norwegian Cancer Society (NO)

Collaboration confirmed with:

- Netherland Cancer Institute (NL)
- Oslo university hospital (NO)
- Institut Curie Hospital (FR)
- Centre Henri Becquerel (FR)
- DKFZ Heidelberg (DE)
- Masaryk Memorial Cancer Institute (CZ)
- Institutul Oncologic (RO)
- Institut Catalá d'Oncologia (ES)
- Arturo López Pérez Foundation (CL)



Cancer Economics WG Session 16th June

”Pricing, Coverage and Access to Innovative Cancer Drugs”

11.00 - Welcome and Update of the European Fair Pricing Network

- Wim van Harten (NL)

11.05 - Access to innovative cancer drugs in Europe

- Sabine Vogler (Austr.)

11.20 - The drug pipeline and financial sustainability of cancer care provision

- Amitabh Chandra (US/Harvard)

11.35 - Innovative policies to reduce drug pricing (review of options and scenarios)

- Nora Franzen, Valesca Retèl (NKI)



Working Group Health Economics

- Thanks to all contributors, WG-board members, WG attendees, Julie van Coppenolle, Stacey Joosten and Simone Koole.

- Contact: i.eekhout@nki.nl

